Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Cevimeline Hydrochloride

Pronunciation: seh-vih-MEH-leen
Class: Cholinergic agent

Trade Names

- Gelatin capsules 30 mg


Cevimeline is a cholinergic agonist that binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands, and increase tone of the smooth muscle in the GI and urinary tracts.



Cevimeline is rapidly absorbed. T max is 1.5 to 2 h. Food decreases the rate of absorption and C max (by 17.3%).


Vd is about 6 L/kg. Cevimeline is less than 20% protein bound. It is extensively bound to tissues.


Cevimeline is metabolized by CYP2D6 and CYP3A3/4.


After 24 h, 84% is excreted in the urine (16% as unchanged drug). The t ½ is about 5 h.

Indications and Usage

Relieves dry mouth in patients with Sjogren syndrome.


Patients with uncontrolled asthma, hypersensitivity to cevimeline, or any condition in which miosis could be harmful (eg, acute iritis, narrow-angle glaucoma).

Dosage and Administration

Dry Mouth with Sjogren Syndrome

PO 30 mg 3 times daily.

Dosage Adjustments

PO Because cevimeline is eliminated extensively in the urine, dosage adjustments may be required for patients with severe renal failure. However, specific recommendations are not established.


Store at room temperature.

Drug Interactions

Anticholinergic medications (eg, atropine, ipratropium bromide, phenothiazines, tricyclic antidepressants)

Cevimeline antagonizes the pharmacologic effects of these medications.

Beta-adrenergic blockers (eg, levobunolol)

Cardiac conduction disturbances possible. Use caution during concomitant therapy.

CYP-450 system

Drugs that inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. Use with caution in individuals known or suspected to be deficient of CYP2D6.

Drugs that induce CYP3A3/4 (eg, aminoglutethimide, barbiturates, carbamazepine, dexamethasone, griseofulvin, modafinil, nafcillin, phenytoin, primidone, rifabutin, rifampin)

Increased cevimeline metabolism; reduced cevimeline concentrations and efficacy possible.

Drugs that inhibit CYP2D6 (eg, amiodarone, fluoxetine, paroxetine, quinidine, ritonavir) or CYP3A3/4 (eg, diltiazem, erythromycin, itraconazole, ketoconazole, verapamil)

Reduced cevimeline metabolism; increased cevimeline concentrations and toxicity possible.


Absorption of cevimeline is decreased when administered with food.

Parasympathomimetics (eg, bethanecol, donepezil, galantamine, neostigmine, physostigmine, pilocarpine, pyridostigmine, rivastigmine, tacrine)

Additive pharmacologic effects and increased toxicity possible.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Dizziness; fatigue.


Excessive sweating.


Nausea; vomiting; diarrhea; dyspepsia.




Back pain; arthralgia.


Sinusitis; upper respiratory tract infection; rhinitis; cough.

Special Senses

Conjunctivitis; excessive salivation; blurred vision; decreased visual acuity; impaired depth perception.


Drugs that inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. Use with caution in individuals known or suspected to be deficient of CYP2D6 activity.




Monitor patient for signs of improvement after therapy is started.

Adverse reactions

Monitor patient for excessive parasympathomimetic, GI, respiratory, CNS, and general body adverse reactions. Notify health care provider if noted and significant.


Category C .




Safety and efficacy not established.


Exercise special care when cevimeline treatment is initiated in an elderly patient, considering the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in the elderly.

Biliary tract

Administer with caution to patients with a history of nephrolithiasis.


Cevimeline can potentially alter cardiac conduction or heart rate. Use with caution in patients with a history of CV disease evidenced by angina pectoris or MI.


Ophthalmic formulations of muscarinic agonists have been reported to cause visual blurring that may result in decreased visual acuity (especially at night and in patients with central lens changes) and impairment of depth perception. Advise caution while driving at night or performing hazardous activities in reduced lighting.


Cevimeline can potentially increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Administer with caution to patients with asthma, chronic bronchitis, or COPD.

Renal colic

Administer with caution to patients with a history of nephrolithiasis.



Headache, visual disturbance, lacrimation, sweating, respiratory distress, GI spasm, nausea, vomiting, diarrhea, AV block, tachycardia, bradycardia, hypotension, hypertension, shock, mental confusion, cardiac arrhythmia, and tremors.

Patient Information

  • Inform patient that cevimeline may cause visual disturbances, especially at night, that could impair their ability to drive safely.
  • If a patient sweats excessively while taking cevimeline, consult health care provider and advise the patient to drink extra water as dehydration may develop.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.